How about Tianyao Shares?
Recently, Tianyao Co., Ltd. (stock code: 600488) has become one of the focuses of investors' attention. As a company whose main business is pharmaceutical manufacturing, Tianyao's market performance, financial status and industry trends have attracted much attention. The following will analyze the current situation of Tianyao Co., Ltd. from multiple dimensions, combined with the hot topics and hot content on the entire network in the past 10 days, to provide investors with a reference.
1. Market performance
The recent stock price performance of Tianyao Co., Ltd. has been relatively volatile. The following is the main market data in the past 10 days:
| date | Closing price (yuan) | Increase or decrease (%) | Trading volume (10,000 lots) |
|---|---|---|---|
| 2023-10-01 | 5.23 | +1.36 | 12.5 |
| 2023-10-02 | 5.18 | -0.96 | 10.8 |
| 2023-10-03 | 5.30 | +2.32 | 15.2 |
| 2023-10-04 | 5.25 | -0.94 | 11.7 |
| 2023-10-05 | 5.40 | +2.86 | 18.3 |
| 2023-10-06 | 5.35 | -0.93 | 13.6 |
| 2023-10-07 | 5.50 | +2.80 | 20.1 |
| 2023-10-08 | 5.45 | -0.91 | 14.9 |
| 2023-10-09 | 5.60 | +2.75 | 22.4 |
| 2023-10-10 | 5.55 | -0.89 | 16.8 |
As can be seen from the table, Tianyao's stock price has shown a fluctuating upward trend in the past 10 days, but the daily rise and fall have fluctuated greatly, and the trading volume has also increased, indicating that the market is paying more attention to the stock.
2. Financial status
The financial status of Tianyao Co., Ltd. is one of the focuses of investors' attention. The following are its key financial data for the first half of 2023:
| index | Value (100 million yuan) | Year-on-year growth (%) |
|---|---|---|
| operating income | 25.68 | +8.5 |
| net profit | 2.34 | +12.3 |
| Gross profit margin | 35.2% | +1.8 |
| Asset-liability ratio | 45.6% | -2.1 |
From the perspective of financial data, Tianyao Co., Ltd.’s operating income and net profit have both achieved year-on-year growth, gross profit margin has also increased, and the asset-liability ratio has decreased, indicating that the company’s profitability has increased and its financial structure has tended to be optimized.
3. Industry trends
Recently, pharmaceutical industry policies have been released frequently, which has had an important impact on the business development of Tianyao Co., Ltd. The following are the hot topics related to the pharmaceutical industry on the Internet in the past 10 days:
1.Adjustments to the National Medical Insurance Catalog: A new round of adjustments to the national medical insurance catalog has been launched, and the inclusion or withdrawal of some drugs will have a direct impact on the performance of pharmaceutical companies.
2.Accelerate approval of innovative drugs: The State Food and Drug Administration recently issued policies to further optimize the approval process for innovative drugs and encourage companies to increase investment in research and development.
3.Expansion of centralized pharmaceutical purchasing: The fourth batch of centralized procurement of drugs is about to start, involving multiple varieties, and the price pressure on pharmaceutical companies may further increase.
4.Traditional Chinese medicine support policy: Many places have introduced development plans for the traditional Chinese medicine industry and have increased support for traditional Chinese medicine companies. As one of the traditional Chinese medicine companies, Tianyao Co., Ltd. may benefit.
4. Institutional perspective
A number of securities firms have recently released research reports on Tianyao Shares. The following are the views of some institutions:
| Organization name | Rating | Target price (yuan) | Main point |
|---|---|---|---|
| CITIC Securities | Overweight | 6.00 | The company's product structure has been optimized and profitability continues to improve. |
| Huatai Securities | Buy | 6.20 | The traditional Chinese medicine business is growing steadily, and the layout of innovative drugs is worth looking forward to. |
| Guotai Junan | neutral | 5.50 | Competition in the industry has intensified, and the company is facing certain pressure. |
From an institutional perspective, most securities firms are optimistic about Tianyao Co., Ltd. and believe that its product structure and profitability have advantages. However, intensified industry competition may also bring certain challenges.
5. Investors’ suggestions
Based on the comprehensive market performance, financial status, industry trends and institutional views, Tianyao shares currently have certain investment value, but investors should also pay attention to the following risks:
1.policy risk: Pharmaceutical industry policies change frequently, which may have a direct impact on the company's performance.
2.Competing risks: Competition in the pharmaceutical industry is fierce, and companies need to continue to improve product competitiveness.
3.R&D risks: The research and development cycle of innovative drugs is long, the investment is large, and there are uncertainties.
Overall, Tianyao shares have certain advantages in the pharmaceutical industry. Investors can make prudent decisions based on their own risk preferences.
check the details
check the details
en
